EGFR
EstablishedEGFR mutation status guides TKI therapy selection in lung cancer; the exon 20 insertion subtype is often resistant and can be missed by standard PCR testing.
EGFR is a receptor that, when mutated, drives a significant share of lung cancers, especially in people who never smoked. A specific, harder-to-detect mutation subtype often doesn't respond to standard pills, and the older, cheaper genetic tests can actually miss up to half of these cases, meaning a more thorough genetic test is sometimes needed.
Epidermal growth factor receptor (EGFR) is a cell-surface receptor tyrosine kinase; activating mutations (most commonly exon 19 deletions and the L858R point mutation) drive a significant subset of non-small cell lung cancer, particularly in never-smokers.
EGFR-mutant NSCLC responds well to EGFR tyrosine kinase inhibitors (TKIs); osimertinib is the current first-line standard for common EGFR mutations, while the less common exon 20 insertion subtype (roughly 4-12% of EGFR mutations) is generally resistant to standard TKIs and represents a genuine unmet treatment need.
Detected via PCR-based mutation testing or NGS panel on tumor tissue or plasma (liquid biopsy); a real diagnostic gap exists since standard PCR-based tests miss up to half of exon 20 insertion variants due to their molecular heterogeneity, requiring NGS for reliable detection of this specific subtype.
Osimertinib resistance eventually develops in most patients, driven by a spectrum of off-target alterations (MET amplification, BRAF, ALK, RET), requiring repeat biopsy or liquid biopsy at progression to identify the specific resistance mechanism and guide next-line treatment selection.
Standard PCR-based tests miss up to ~50% of exon 20 insertion variants, a genuine diagnostic gap requiring NGS for reliable detection.
- Cancer Treatment Reviews. (2023). The state of the art of EGFR exon 20 insertions in non-small cell lung cancer.
- Translational Lung Cancer Research. (2023). EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer.